Insights from ESMO24 - Exact Sciences Educational Symposium
Tools to Guide Treatment Decisions in Early Breast Cancer: Genomic Testing and Emerging Role of MRD
Events based video library
ESMO 2024 Satellite symposium recording
[ESMO24] Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.[ESMO24] Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.[ESMO24] Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.[ESMO24] Optimizing the approach to MRD assay development
Rick Baehner provides a topline overview of ongoing research into the development of MRD assays.EBCC 2024 Satellite symposium recording
[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!
Evolving clinical practice for multi-gene assays: what’s new![EBCC24] Implications of updated guidelines for MGAs: Introduction
Implications of updated guidelines for MGAs: Introduction[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient
Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.[EBCC24] Challenging cases: N1 – premenopausal
Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help...Other webinar and event recordings
Insights & perspectives from a centralized laboratory in genomic testing
Listen Rick Baehner, MD and Helen Bailey, MD share insights of a centralized laboratory & give perspectives how expertise in genomic testing will...
The pathologist's impact on clinical practice & patients' lives
Hear Prof. Giancarlo Pruneri of the University of Milan providing his insights on the importance of analytical work and the critical need to...
The development of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the analytical validation and the key clinical attributes of the the Oncotype...
Clinical validation of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the clinical validation of the Oncotype DX® test in TAILORx (N0 population)...
Future of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the Oncotype DX® test in ongoing trials.
Cancer Network Podcast, S1 Ep17
Drs. Alison Laws, Philip Poorvu, and Sara Hurvitz discuss the utility of the Breast Recurrence Score® test for node-positive, HR+, HER2- breast cancer patients.
Challenging Node-positive Case Studies Webinar
Hear Drs. Jeremy Force and Christy Russell discuss how physicians can use the Breast Recurrence Score test and the recently presented data from the RxPONDER trial to inform chemotherapy decisions for HR-positive, HER2-negative breast cancer patients.
Applying RxPONDER to Clinical Practice: Miami Breast Cancer Conference 2021 Product Theater
At the 2021 Miami Breast Cancer Conference, Drs. Tari King and Kathy Miller discuss lymph node-positive breast cancer cases with Dr. Christy Russell.
Get in touch
Have questions about Oncotype DX®?
